NCT02091141: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR, BRAF, ALK, TMB-H, SMO, PTCH
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: If not HER2+, patients must have EGFR, BRAF, ALK, PD-L1, hedgehog (SMO) mutations, and/or loss-of-function PTCH-1 mutation
Exclusions: Patients with active or untreated brain metastases

Comments are closed.

Up ↑